New drug trial aims to shrink bulging eyes, fix double vision
NCT ID NCT07152392
Summary
This study is testing an investigational drug called IBI311 in people with inactive but moderate-to-severe Thyroid Eye Disease (TAO). The goal is to see if the drug can safely reduce eye bulging (proptosis) and improve double vision. Researchers will enroll about 50 participants to measure changes in these symptoms and monitor for any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID ASSOCIATED OPHTHALMOPATHIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Changzheng Hospital
RECRUITINGShanghai, Shanghai Municipality, 200003, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.